Sandler Alan B.
Known title: Chief Development OfficerCIK: 0001835966
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Transaction History
| RVMD | ▲ Buy | Option Exercise | 6,000 | $353K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 2,200 | $442K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 1,609 | $325K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 1,000 | $203K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 1,199 | $244K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 301 | $62K | 9/29/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 5 | $975 | 9/16/2026 | View on chart |
| RVMD | ▼ Sell | Open Market | 336 | $67K | 9/16/2026 | View on chart |
| ZLAB | ▲ Buy | Option Exercise | 1,060 | $0 | 4/1/2022 | View on chart |
| ZLAB | ▼ Sell | Tax Withholding | 2,075 | $148K | 12/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.